NEW YORK, April 17, 2023 (GLOBE NEWSWIRE) — Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today released preclinical data on TALEN-edited MUC1 CAR T-cells at the American Association for Cancer Research (AACR)…Read More
Cellectis Presents Preclinical Data on TALENedited MUC1 CAR Tcells to Enhance Efficacy in Targeting Triple Negative Breast Cancer at the American Association for Cancer Research AACR Annual Meeting
